Pasi A. Jänne, MD, PhD

MADRID — Pasi Jänne, MD, PhD, discussed the “encouraging” clinical activity of adagrasib with pembrolizumab in patients with KRAS G12C-mutated advanced non-small cell lung cancer in a video interview with Healio at ESMO Congress.

In this video, Pasi Jänne, MD, PhD, professor of medicine, Harvard Medical School, discussed studies looking at combining therapies with sotorasib. Those combinations included sotorasib and trametinib for KRAS p.G12C-mutated solid tumors and sotorasib and afatinib for KRAS p.G12C mutated non-small cell lung cancer.

In this video, Pasi Jänne, MD, PhD, Professor of Medicine, Harvard Medical School, discusses a session on KRAS mutant lung cancers presented at AACR-NCI-EORTC. In the session, new KRAS inhibitors that bind to the novel mutations were discussed.

In an interview with Healio, Pasi A. Jänne, MD, PhD, discussed a study on the use of an antibody-drug conjugate in some patients with non-small cell lung cancer.

In this video, Pasi A. Jänne, MD, PhD, director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and professor of medicine at Harvard Medical School, discusses results from the IMpower010 study presented at ESMO 2021.

In this video, Pasi A. Jänne, MD, PhD, director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and professor of medicine at Harvard Medical School, discusses results from the DESTINY-Lung01 study presented at ESMO 2021.

In this video, Pasi A. Jänne, MD, PhD, discussed updated data from the phase 2 CodeBreak100 trial presented at the virtual ASCO Annual Meeting.

In this video, Pasi A. Jänne, MD, PhD, spoke with Healio about data from the IMpower010 trial presented at the virtual ASCO Annual Meeting.

In this video, Pasi A. Jänne, MD, PhD, spoke with Healio about safety and efficacy data from a phase 1 trial of patritumab deruxtecan, HER3-DXd, he presented at the virtual ASCO Annual Meeting.